⌘K
t
ANGLE plc announced that it received valid applications for 3,561,121 Open Offer Shares from Qualifying Shareholders, raising gross proceeds of £0.5m. In aggregate, the Company has raised £9.3m of gross proceeds from the Placing, Subscription, and Open Offer. Admission and settlement of the Open Offer Shares are expected on 24 June 2024, resulting in a total of 322,641,668 ordinary shares in issue.
| Date | 21 Jun 2024 |
| Time | 07:00:12 |
| Category | Capital structure |
| ID | 3674T |
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. |
|
|
|
21 June 2024 |
ANGLE plc (the "Company")
Results of Open Offer
ANGLE plc (AIM:AGL), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that, pursuant to the Open Offer announced on 5 June 2024, it has received valid applications for a total of 3,561,121 Open Offer Shares from Qualifying Shareholders.
The Open Offer raised gross proceeds of £0.5m at the Issue Price, which will be used to strengthen the Company's balance sheet. In aggregate, £9.3m of gross proceeds have been raised pursuant to the Placing, Subscription and Open Offer.
The Open Offer Shares, when issued, will be fully paid and rank pari passu in all respects with the existing ordinary shares of the Company. Application has been made for the Open Offer Shares to be admitted to trading on AIM. Admission and settlement of the Open Offer Shares is expected to take place at 8.00 a.m. on 24 June 2024.
Total voting rights
Following Second Admission, the Company will have a total of 322,641,668 ordinary shares in issue. With effect from Second Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Unless otherwise stated, capitalised terms not otherwise defined in the text of this announcement have the same meanings ascribed to them as in the Launch Announcement published by the Company on 5 June 2024.
For further information:
|
ANGLE plc |
+44 (0) 1483 343434 |
|
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
|
|
Berenberg (NOMAD & Corporate Broker) Toby Flaux, Ciaran Walsh, Milo Bonser, Brooke Harris-Lowing |
+44 (0) 20 3207 7800 |
|
FTI Consulting (Financial PR) Simon Conway, Ciara Martin Matthew Ventimiglia (US) |
+44 (0) 203 727 1000 +1 (212) 850 5624 |
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit https://angleplc.com/.